Cravit-based sequential therapy — Competitive Intelligence Brief

Cravit-based sequential therapy (Cravit-based sequential therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone antibiotic (as part of sequential therapy regimen). Area: Infectious Disease / Gastroenterology.

marketed Fluoroquinolone antibiotic (as part of sequential therapy regimen) Bacterial DNA gyrase and topoisomerase IV Infectious Disease / Gastroenterology Small molecule

Target snapshot

Cravit-based sequential therapy (Cravit-based sequential therapy) — National Taiwan University Hospital. Cravit-based sequential therapy uses levofloxacin (a fluoroquinolone antibiotic) as part of a multi-drug sequential regimen to eradicate Helicobacter pylori infection.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cravit-based sequential therapy TARGET	Cravit-based sequential therapy	National Taiwan University Hospital	marketed	Fluoroquinolone antibiotic (as part of sequential therapy regimen)	Bacterial DNA gyrase and topoisomerase IV
Third generation fluoroquinolone	Third generation fluoroquinolone	University of Roma La Sapienza	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
moxifloxacin 0.5% HCI ophthalmic solution	moxifloxacin 0.5% HCI ophthalmic solution	Allergan	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Moxifloxacin 0.5% ophthalmic solution	Moxifloxacin 0.5% ophthalmic solution	Johns Hopkins University	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
moxifloxacin 0.5% eye drops	moxifloxacin 0.5% eye drops	Allergan	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
levofloxacin-based triple therapy	levofloxacin-based triple therapy	National Taiwan University Hospital	marketed	Fluoroquinolone antibiotic (in combination therapy)	Bacterial DNA gyrase and topoisomerase IV
Moxifloxacin (Topical)	Moxifloxacin (Topical)	University of California, San Francisco	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoroquinolone antibiotic (as part of sequential therapy regimen) class)

1. National Taiwan University Hospital · 1 drug in this class